Elizabeth J Bell1, Paul A Decker2, Michael Y Tsai3, James S Pankow4, Naomi Q Hanson3, Christina L Wassel5, Nicholas B Larson2, Kevin P Cohoon1, Matthew J Budoff6, Joseph F Polak7, James H Stein8, Suzette J Bielinski9. 1. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. 2. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 3. Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. 4. Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA. 5. Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Colchester, VT, USA. 6. Los Angeles Biomedical Research Institute, Torrance, CA, USA. 7. Tufts University School of Medicine, Boston, MA, USA. 8. Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 9. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. Electronic address: bielinski.suzette@mayo.edu.
Abstract
BACKGROUND AND AIMS: Hepatocyte growth factor (HGF) has previously been associated with risk of stroke, coronary heart disease, and atherosclerosis. We hypothesized that higher circulating HGF is associated with greater progression of measures of atherosclerosis: coronary artery calcium (CAC) and carotid plaque. METHODS: Participants aged 45-84 years from the prospective cohort study Multi-Ethnic Study of Atherosclerosis had HGF measured at baseline (between 2000 and 2002) and were followed for progression of atherosclerosis for up to 12 years. CAC was measured at all five exams using the Agatston method. Mixed-effects models were used to examine the association of HGF and CAC progression among 6695 participants with available data. Relative risk regression was used to assess the association between HGF and new or additional carotid plaque between exams 1 and 5 in 3400 participants with available data. All point estimates were adjusted for potential confounding variables. RESULTS: Each standard deviation higher HGF at baseline was associated with 2.9 Agatston units/year greater CAC progression (95% CI: 1.6-4.2, p < 0.0001), and the magnitude of this association differed by race/ethnicity (p value for interaction by race = 0.003). Each standard deviation higher HGF at baseline was associated with a 4% higher risk of new or additional carotid plaque (95% CI: 1.01-1.08, p = 0.005). CONCLUSIONS: Higher levels of HGF were significantly associated with greater progression of atherosclerosis in this large and diverse population. Circulating HGF continues to show promise as a potential clinical biomarker for cardiovascular disease.
BACKGROUND AND AIMS: Hepatocyte growth factor (HGF) has previously been associated with risk of stroke, coronary heart disease, and atherosclerosis. We hypothesized that higher circulating HGF is associated with greater progression of measures of atherosclerosis: coronary artery calcium (CAC) and carotid plaque. METHODS:Participants aged 45-84 years from the prospective cohort study Multi-Ethnic Study of Atherosclerosis had HGF measured at baseline (between 2000 and 2002) and were followed for progression of atherosclerosis for up to 12 years. CAC was measured at all five exams using the Agatston method. Mixed-effects models were used to examine the association of HGF and CAC progression among 6695 participants with available data. Relative risk regression was used to assess the association between HGF and new or additional carotid plaque between exams 1 and 5 in 3400 participants with available data. All point estimates were adjusted for potential confounding variables. RESULTS: Each standard deviation higher HGF at baseline was associated with 2.9 Agatston units/year greater CAC progression (95% CI: 1.6-4.2, p < 0.0001), and the magnitude of this association differed by race/ethnicity (p value for interaction by race = 0.003). Each standard deviation higher HGF at baseline was associated with a 4% higher risk of new or additional carotid plaque (95% CI: 1.01-1.08, p = 0.005). CONCLUSIONS: Higher levels of HGF were significantly associated with greater progression of atherosclerosis in this large and diverse population. Circulating HGF continues to show promise as a potential clinical biomarker for cardiovascular disease.
Authors: J Jeffrey Carr; Jennifer Clark Nelson; Nathan D Wong; Michael McNitt-Gray; Yadon Arad; David R Jacobs; Stephan Sidney; Diane E Bild; O Dale Williams; Robert C Detrano Journal: Radiology Date: 2005-01 Impact factor: 11.105
Authors: John W McEvoy; Michael J Blaha; Andrew P Defilippis; Matthew J Budoff; Khurram Nasir; Roger S Blumenthal; Steven R Jones Journal: J Am Coll Cardiol Date: 2010-11-09 Impact factor: 24.094
Authors: Y Liu; F L Wilkinson; J P Kirton; M Jeziorska; H Iizasa; Y Sai; E Nakashima; A M Heagerty; A E Canfield; M Y Alexander Journal: J Pathol Date: 2007-05 Impact factor: 7.996
Authors: Y Taniyama; R Morishita; H Nakagami; A Moriguchi; H Sakonjo; K Matsumoto; T Nakamura; J Higaki; T Ogihara Journal: Circulation Date: 2000-07-11 Impact factor: 29.690
Authors: Anne B Newman; Barbara L Naydeck; Diane G Ives; Robert M Boudreau; Kim Sutton-Tyrrell; Daniel H O'Leary; Lewis H Kuller Journal: Am J Cardiol Date: 2008-01-15 Impact factor: 2.778
Authors: Oluseye Ogunmoroti; Olatokunbo Osibogun; Richard A Ferraro; Paul M Ndunda; Nicholas B Larson; Paul A Decker; Suzette J Bielinski; Roger S Blumenthal; Matthew J Budoff; Erin D Michos Journal: Open Heart Date: 2022-05
Authors: Richard A Ferraro; Oluseye Ogunmoroti; Di Zhao; Chiadi E Ndumele; Vishal Rao; Ambarish Pandey; Nicholas B Larson; Suzette J Bielinski; Erin D Michos Journal: J Card Fail Date: 2021-05-26 Impact factor: 6.592
Authors: Kristina Navrazhina; Sandra Garcet; Juana Gonzalez; David Grand; John W Frew; James G Krueger Journal: J Invest Dermatol Date: 2021-03-22 Impact factor: 7.590
Authors: Hannah K Drescher; Fabienne Schumacher; Teresa Schenker; Maike Baues; Twan Lammers; Thomas Hieronymus; Christian Trautwein; Konrad L Streetz; Daniela C Kroy Journal: Oxid Med Cell Longev Date: 2018-11-12 Impact factor: 6.543
Authors: Lars Wallentin; Niclas Eriksson; Maciej Olszowka; Tanja B Grammer; Emil Hagström; Claes Held; Marcus E Kleber; Wolfgang Koenig; Winfried März; Ralph A H Stewart; Harvey D White; Mikael Åberg; Agneta Siegbahn Journal: PLoS Med Date: 2021-01-13 Impact factor: 11.069
Authors: Ashok Kumar Kumawat; Mulugeta M Zegeye; Geena Varghese Paramel; Roland Baumgartner; Anton Gisterå; Obed Amegavie; Sanna Hellberg; Hong Jin; April S Caravaca; Leif Å Söderström; Lindvi Gudmundsdotter; Fredrik Y Frejd; Liza U Ljungberg; Peder S Olofsson; Daniel F J Ketelhuth; Allan Sirsjö Journal: Front Cardiovasc Med Date: 2022-02-24
Authors: Olatokunbo Osibogun; Oluseye Ogunmoroti; Richard A Ferraro; Chiadi E Ndumele; Gregory L Burke; Nicholas B Larson; Suzette J Bielinski; Erin D Michos Journal: Front Cardiovasc Med Date: 2022-01-03